Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Lyell Immunopharma, Inc. Director's Dealing 2025

Jun 11, 2025

33362_dirs_2025-06-11_46cf89df-bb96-4164-ab2d-08941232fb0c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-06-09

Reporting Person: Bachleda Mark (N/A)

More from Lyell Immunopharma, Inc.

Annual Report 2026
Apr 24
Regulatory Filings 2026
Apr 3
Director's Dealing 2026
Feb 12
Director's Dealing 2026
Feb 12
Director's Dealing 2026
Feb 12
Director's Dealing 2026
Feb 11
Director's Dealing 2026
Feb 11
Director's Dealing 2026
Feb 11
Director's Dealing 2026
Feb 11
Director's Dealing 2026
Feb 11
View all filings →